Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica | MicrobiomeTrials← Back to trialsNCT07279688
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-12-18Est. Completion: 2028-11
Enrollment target: 140 participants Locations- VIDAL François, Aix-en-Provence, France
- LEGRAND Jean-Louis, Arras, France
- Besançon-CIC, Besançon, France
- PRATI Clément, Besançon, France
- CHU de Bordeaux Pellegrin, Bordeaux, France
- Dr Alain SARAUX, Brest, France
- RAT Anne-Christine, Caen, France
- LESKE Charles, Cholet, France
- TOURNADRE Anne, Clermont-Ferrand, France
- RAMON André, Dijon, France
- APHP - Kremlin-Bicêtre, Le Kremlin-Bicêtre, France
- DIREZ Guillaume, Le Mans, France
- FLIPO René-Marc, Lille, France
- WIRTH Théo, Marseille, France
- LE HENAFF Catherine, Morlaix, France
- CHU de Nice, Nice, France
- FAUTREL Bruno - AP-HP La Pitié-Salpétrière, Paris, France
- OTTAVIANI Sébastien - AP-HP Bichat, Paris, France
- CHU Reims, Reims, France
- GOTTENBERG Jacques-Eric, Strasbourg, France
- CHU de Toulouse, Toulouse, France
- CARVAJAL ALEGRIA Guillermo, Tours, France
Other microbiome trials you might be interested in
Polymyalgia Rheumatica
Polymyalgia rheumatic (PMR) is a frequent inflammatory disease. It affects the elderly, with peak incidences at the age …
Brest, FranceCompleted Oct 21, 2021
Polymyalgia Rheumatica
This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatme…
Denver, United StatesEst. completion Jun 4, 2029